Skip to main content

Table 3 Demographics and chart review of patients who developed corneal epithelial changes

From: Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors

 CaseDrugSexAgeDiagnosisCorneal FeaturesDuration of chemotherapy (day)Interval 1 (day)Interval 2 (day)Visual acuity before chemotherapy (log MAR)Lowest visual acuity after chemothearpy (log MAR)Highest visual acuity after end of therapy (log MAR)Corneal clearance
ODOSODOSODOS
EGFR inhibitor (Tyrosine Kinase Inhibitor)1Vandetanib230–39NSCLCVortex Keratopathy28491Deceased000000N/A
2260–69NSCLC390395F/u loss0.0970.0970.3010.1550.0970.097partial
3270–79NSCLC2532522300.1550.1550.2220.3010.2220.155total
4Osimertinib250–59NSCLCOngoing196Ongoing000.1550.155N/AN/AN/A
5ABT-414150–59Glioblastoma593559011.22220.6990.523partial
6270–79Glioblastoma231491410.0460.3010.5230.52300.097total
7250–59Glioblastoma34723181000.5230.30100total
8140–49Glioblastoma1112279000.3010.22200total
9260–69Glioblastoma1422149000.3010.69900total
FGFR inhibitor10ASP5878240–49HCCCorneal epithelial changes mimicking dysmaturation1955593000.3010.15500total
11FPA144240–49Gastric cancer45973218000.0460.39800total
12260–69Gastric cancer7068F/u loss000.1550.0460.0970.046partial
  1. EGFR epidermal growth factor receptor, FGFR fibroblast growth factor receptor, NSCLC Non-small cell lung cancer, HCC Hepatocellular carcinoma, Interval 1 Interval between start of chemotherapy and diagnosis of corneal change (day), Interval 2 Interval between end of chemotherapy and corneal recovery (day), OD Oculus Dextra (right eye), OS Oculus Sinistra (left eye), logMAR logarithm of minimal angle of resolution units, N/A Not applicable
\